Brief: Immix Biopharma Subsidiary Nexcella Completes Pre-Ind Meeting With FDA On Nxc-201 Us Clinical Trial
26/06/2023 19:28
June 26 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIX BIOPHARMA SUBSIDIARY NEXCELLA COMPLETES PRE-IND
MEETING
WITH FDA ON NXC-201 US CLINICAL TRIAL
Source text for Eikon: ID:nGNX53pDQD
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary